- Anavex Life Sciences' (NASDAQ:AVXL) oral drug candidate blarcamesine (ANAVEX2-73) slowed cognitive decline in a phase 2b/3 study.
- Shares are up ~3% in Thursday premarket trading.
- The trial was conducted in ~500 participants with early symptoms of Alzheimer's, including mild cognitive impairment and mild dementia. Patients were randomized to receive blarcamesine or placebo once daily over 48 weeks.
- Results showed clinically significant differences in ADAS-Cog13 and CDR-SB, two Alzheimer's disease assessment scales, between the treatment and placebo arms.
- In addition, biomarkers of amyloid beta, a plaque found in the brains of those with Alzheimer's, indicated anti-amyloid effects of blarcamesine. Also, brain MRIs showed a significant reduction in brain volume loss in the blarcamesine-treated group.
- Anavex (AVXL) said that blarcamesine "restores cellular homeostasis by targeting sigma-1 and muscarinic receptors."
- Forums
- ASX - By Stock
- CGS
- More good news
CGS
cogstate ltd
Add to My Watchlist
2.79%
!
$1.84

More good news
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.84 |
Change
0.050(2.79%) |
Mkt cap ! $312.3M |
Open | High | Low | Value | Volume |
$1.81 | $1.84 | $1.79 | $19.96K | 11.05K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2500 | $1.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.84 | 1424 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2500 | 1.800 |
2 | 6424 | 1.790 |
1 | 1000 | 1.785 |
1 | 2723 | 1.780 |
1 | 278 | 1.770 |
Price($) | Vol. | No. |
---|---|---|
1.850 | 300 | 1 |
1.880 | 2426 | 1 |
1.900 | 4400 | 1 |
2.000 | 150000 | 1 |
2.100 | 3000 | 1 |
Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
Featured News
CGS (ASX) Chart |
The Watchlist
P.HOTC
HotCopper
Frazer Bourchier, Director, President and CEO
Frazer Bourchier
Director, President and CEO
SPONSORED BY The Market Online